SCHEMBL571120

SCHEMBL571120

CCCCC1=C(C)C(=O)c2ccccc2C1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 4/20 0.54
ALDH1A1 P00352 5/20 0.50
MAPT P10636 5/20 0.50
TDP1 Q9NUW8 2/20 0.50
KDM4E B2RXH2 2/20 0.50
LMNA P02545 2/20 0.50
HTT P42858 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
APAF1 O14727 2/20 0.50
MITF O75030 1/20 0.50
S100A4 P26447 3/20 0.49
CDC25A P30304 2/20 0.49
CDC25B P30305 2/20 0.49
THRB P10828 1/20 0.49
MAP2K7 O14733 1/20 0.49
TBXAS1 P24557 1/20 0.46
PTPN1 P18031 1/20 0.46
AURKA O14965 1/20 0.46
AURKB Q96GD4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL572112 0.95 ALDH1A1 (0.56) PKMALDH1A1MAPTTDP1KDM4E
SCHEMBL572045 0.93 ALDH1A1 (0.58) PKMALDH1A1MAPTTDP1KDM4E
SCHEMBL571607 0.93 ALDH1A1 (0.58) PKMALDH1A1MAPTTDP1KDM4E
SCHEMBL572005 0.93 ALDH1A1 (0.58) PKMALDH1A1MAPTTDP1KDM4E
SCHEMBL571286 0.93 ALDH1A1 (0.58) PKMALDH1A1MAPTTDP1KDM4E
SCHEMBL572109 0.93 ALDH1A1 (0.58) PKMALDH1A1MAPTTDP1KDM4E
SCHEMBL571040 0.93 ALDH1A1 (0.58) PKMALDH1A1MAPTTDP1KDM4E
SCHEMBL571017 0.93 ALDH1A1 (0.58) PKMALDH1A1MAPTTDP1KDM4E
SCHEMBL15695046 0.93 ALDH1A1 (0.58) PKMALDH1A1MAPTTDP1KDM4E
SCHEMBL17296068 0.93 ALDH1A1 (0.58) PKMALDH1A1MAPTTDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3615502-B1 THERAPEUTIC COMPOUNDS AND METHODS UNIV TASMANIA (AU) 2023-06-21 EP disclosed
US-10934253-B2 Therapeutic compounds and methods UNIVERSITY OF TASMANIA (AU) 2021-03-02 US disclosed
US-20200131119-A1 THERAPEUTIC COMPOUNDS AND METHODS UNIVERSITY OF TASMANIA (AU) 2020-04-30 US disclosed
WO-2015183985-A2 THERAPEUTIC COMPOSITIONS INCLUDING NAPHTHOQUINONES AND USES THEREOF STEALTH PEPTIDES INTERNATIONAL, INC. (MC) 2015-12-03 WO disclosed
EP-2600857-A2 TREATMENT OF MITOCHONDRIAL DISEASES WITH NAPHTHOQUINONES Edison Pharmaceuticals, Inc. (US) 2013-06-12 EP disclosed
WO-2012019029-A2 TREATMENT OF MITOCHONDRIAL DISEASES WITH NAPHTHOQUINONES EDISON PHARMACEUTICALS, INC. (US) 2012-02-09 WO disclosed
US-7544438-B2 Electron mediator, electron mediator immobilized electrode, and biofuel cell using the electrode DAIICHI PURE CHEMICALS CO., LTD (JP) 2009-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200131119-A1 THERAPEUTIC COMPOUNDS AND METHODS UQCRC1, COX5B, CS PKM 274/4885ALDH1A1 523/4885MAPT 1209/4885
US-10934253-B2 Therapeutic compounds and methods UQCRC1, COX5B, CS PKM 274/4885ALDH1A1 523/4885MAPT 1209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.